Gastrointestinal (GI) disorders, including functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn’s disease (CD) and colitis, afflict more than one in five Americans, particularly women. While some GI disorders may be controlled by diet and pharmaceutical medications, others are poorly moderated by conventional treatments. Symptoms of GI disorders often include cramping, abdominal pain, inflammation of the lining of the large and/or small intestine, chronic diarrhea, rectal bleeding and weight loss.
Patients with these disorders frequently report using cannabis therapeutically to address a variety of symptoms, including abdominal pain, abdominal cramping, and diarrhea. [1-9]According to survey data published in 2011 in the European Journal of Gastroenterology & Hepatology, “Cannabis use is common amongst patients with IBD for symptom relief, particularly amongst those with a history of abdominal surgery, chronic abdominal pain and/or a low quality of life index.” More recent survey data of IBD patients affirms: “[A] significant number of patients with IBD currently use marijuana. Most patients find it very helpful for symptom control.”
Preclinical studies demonstrate that activation of the CB1 and CB2 cannabinoid receptors exert biological functions on the gastrointestinal tract. Effects of their activation in animals include suppression of gastrointestinal motility, inhibition of intestinal secretion, reduced acid reflux, and protection from inflammation, as well as the promotion of epithelial wound healing in human tissue. Experts suggest the endogenous cannabinoid system plays “a key role in the pathogenesis of IBD,” and that “cannabinoids may, therefore, be beneficial in inflammatory disorders” such as colitis and other digestive diseases.
Observational trial data reports that whole-plant cannabis therapy is associated with a reduction in Crohn’s disease activity and disease-related hospitalizations. Investigators at the Meir Medical Center, Institute of Gastroenterology and Hepatology assessed ‘disease activity, use of medication, need for surgery, and hospitalization’ before and after cannabis use in 30 patients with CD. Authors reported, “All patients stated that consuming cannabis had a positive effect on their disease activity” and documented “significant improvement” in 21 subjects.
Specifically, researchers found that subjects who consumed cannabis “significantly reduced” their need for other medications. Participants in the trial also reported requiring fewer surgeries following their use of cannabis. “Fifteen of the patients had 19 surgeries during an average period of nine years before cannabis use, but only two required surgery during an average period of three years of cannabis use,” authors reported. They concluded: “The results indicate that cannabis may have a positive effect on disease activity, as reflected by a reduction in disease activity index and in the need for other drugs and surgery.”
In a follow up, randomized placebo-controlled trial, inhaled cannabis was reported to decrease Crohn’s disease symptoms in subjects with a treatment-resistant form of the disease. Nearly half of the patients in the trial achieved disease remission. By contrast, the administration of oral CBD was not found to have a beneficial therapeutic effect in Crohn’s disease patients in a controlled trial setting.
Based on the available evidence to date, some experts now opine that modulation of the ECS represents a novel therapeutic approach for the treatment of numerous GI disorders — including inflammatory bowel disease, functional bowel diseases, gastro-oesophagael reflux conditions, secretory diarrhea, gastric ulcers and colon cancer.[23-25]
 Gahlinger, Paul M. 1984. Gastrointestinal illness and cannabis use in a rural Canadian community. Journal of Psychoactive Drugs 16: 263-265.
 Swift et al. 2005. Survey of Australians using cannabis for medical purposes. Harm Reduction Journal 4: 2-18.
 Bruce et al. 2017. Preferences for medical marijuana over prescription medications among persons living with chronic conditions: Alternative, complimentary, and tapering uses. Journal of Complimentary Medicine [online ahead of print].
 Rahman et al. 2017. Drug-herb interactions in the elderly patient with IBD: A growing concern. Current Treatment Options in Gastroenterology [online ahead of print].
 Storr et al. 2014. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflammatory Bowel Diseases 20: 472-480.
 Weiss and Friedenberg. 2015. Patterns of cannabis use in patients with Inflammatory Bowel Disease: A population based analysis. Drug and Alcohol Dependence 156: 84-89.
 Hasenoehri et al. 2017. Cannabinoids for treating inflammatory bowel diseases: Whare are we and where do we go? Expert Review of Gastroenterology & Hepatology 11: 329-337.
 Lal et al. 2011. Cannabis use among patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 23: 891-896.
 Ravikoff et al. 2013. Marijuana use patterns among patients with inflammatory bowel disease. Inflammatory Bowel Diseases 19: 2809-2814.
 DiCarlo and Izzo. 2003. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opinion on Investigational Drugs 12: 39-49.
 Lehmann et al. 2002. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 123: 1129-1134.
 Massa et al. 2005. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. Journal of Molecular Medicine 12: 944-954.
 Wright et al. 2005. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453.
 Ahmed and Katz. 2016. Therapeutic use of cannabis in Inflammatory Bowel Disease. Gastroenterology & Hepatology 12: 668-679.
 Naftali et al. 2011. Treatment of Crohn’s disease with cannabis: an observational study. Journal of the Israeli Medical Association 13: 455-458.
 Naftali et al. 2013. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology 11: 1276-1280.
 Natfali et al. 2017. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Digestive Diseases 62: 1615-1620.
 Massa and Monory. 2006. op. cit.
 Izzo et al. 2009. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.Trends in Pharmacological Sciences 30: 515-527.